Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Dabrafenib, and Trametinib in BRAF-Mutated Anaplastic Thyroid Cancer
NCT04675710Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2021
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in anaplastic thyroid cancer (ATC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2021; status: active, not recruiting.
02
Drugs
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT04675710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675710.